Clinical Trials Directory

We are doing this study to find out if an experimental drug called ASP2138 (the study drug) is a safe and effective option for people with gastroesophageal junction (GEJ) cancer or metastatic pancreatic cancer.

This study has three parts: - Screening (up to 21 days): You'll get health checks like heart tests, scans, and blood work. - Study Drug Period (28-day cycles): You'll be randomly placed in one of two groups: - One group gets AZD3632 alone. -The other gets AZD3632 with another medicine called posaconazole. You'll have regular visits for tests and questions. - After Treatment: You'll have a safety check 30 days after your last dose, then visits every 12 weeks to see how your disease is doing.

We are doing this study to find out if an experimental drug called ataciguant (the study drug) is an effective option to slow the rate of calcium deposits in the aortic valve for people who have aortic stenosis.

We are doing this study to find out if an experimental drug called RGX-314 (the study drug) is a safe and effective treatment for wet macular degeneration (WMD). RGX-314 is an experimental gene therapy drug that is designed to make people's bodies produce a protein that blocks the production of a bodily substance called vascular endothelial growth factor (VEGF). We want to know if this drug can continually block the production of VEGF, which might help prevent fluid build-up in the eye.

We are doing this study to find out if an experimental drug called efzofitimod (the study drug) is a safe and effective option for people with SSc-ILD. We want to know how well the study drug works against the skin and lung effects caused by SSc-ILD.

We are doing this study to find out if a study drug called belzupacap sarotalocan (bel-sar) is a safe and effective option when it is combined with laser light therapy for people who have a type of eye cancer called an indeterminate lesion (a growth in your eye that is suspected to be melanoma) or choroidal melanoma, which is also known as eye melanoma.

This study is testing a new medicine called MYK-224 to help people with a heart problem called HFpEF. That means their heart pumps well but does not relax properly. People in the study also have signs that their heart is not working normally. The study has four groups, called cohorts. Duke is only helping with Cohort 4, which will include about 160 people. These people will be split into four smaller groups. Three groups will get different amounts of the real medicine, and one group will get a fake medicine called a placebo. The treatment will last 20 weeks. A special team of doctors will check to make sure the medicine is safe and decide how much each group should get. To join the study, people must meet certain health rules.